Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Expert insights reveal how 3D cellular models are revolutionising preclinical testing and clinical translation.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to ...

Recently, with the in-depth study of biological network structures, methods such as graph neural networks and graph contrastive learning have attracted significant attention and demonstrated notable ...

Organ-on-a-chip systems offer a more accurate, ethical, and scalable alternative to animal testing in drug discovery and ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is ...

PORTLAND, IN, UNITED STATES, July 3, 2025 /EINPresswire.com/ -- According to the report, the global animal model market was valued at $1.9 billion in 2022 and is estimated to reach $3.6 billion by ...

A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts ...

UB scientists Ram Samudrala, PhD, and Zackary M. Falls, PhD, talk about the new platform to make drug discovery faster and less expensive while also being safe and effective.

Advances in computational biology, bioinformatics, artificial intelligence (AI), and high-performance computing have dramatically accelerated the ...

Optibrium, a leading developer of software and AI solutions for molecular design, today announced its partnership with ...